317450 - Myungin Pharm

317450 Summary

Biopharma

Stock Price & Overview

₩44,650 +0 (+0.00%) Close · Sep 4, 2026 KST

KOSPI | ₩KRW | Close: ₩44,650 ≈ US$32 · Market cap ₩0.7tn (≈ $466m)

317450 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023
Total Revenue	287.3	269.4	242.3
Cost of Revenue	113.3	100.6	88.4
Gross Profit	174.0	168.9	153.9
Selling, General & Administrative	81.0	76.4	70.2
Operating Income	92.5	92.8	83.6
Finance Income	10.3	14.6	9.1
Finance Costs	0.9	9.2	1.2
Pretax Income	102.1	88.1	92.1
Income Tax Expense	20.7	19.4	17.5
Net Income	81.4	68.7	74.5
Total Comprehensive Income	80.0	64.2	70.7

Breakdown ₩ bn	FY2025	FY2024	FY2023
Total Assets	841.7	581.7	521.6
Current Assets	643.3	385.8	307.6
Cash & Cash Equivalents	31.8	32.9	34.4
Inventories	64.1	60.3	56.3
Trade Receivables	63.7	60.8	58.1
Non-current Assets	198.4	195.9	214.0
Property, Plant & Equipment	116.6	95.1	94.1
Intangible Assets	5.5	0.7	0.7
Total Liabilities	47.3	49.9	49.3
Current Liabilities	46.2	44.6	39.2
Non-current Liabilities	1.1	5.3	10.1
Total Equity	794.4	531.8	472.3
Share Capital	7.3	5.6	5.6
Retained Earnings	602.4	533.3	471.7

Breakdown ₩ bn	FY2025	FY2024	FY2023
Cash from Operating Activities	81.6	83.0	76.1
Cash from Investing Activities	-263.5	-76.9	-39.8
Purchase of Property, Plant & Equipment	30.0	10.2	4.6
Cash from Financing Activities	181.1	-7.7	-20.0
Dividends Paid	11.2	5.6	22.4
Net Change in Cash	-0.9	-1.6	16.2

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3
Total Revenue	76.1	72.1	72.1	72.7
Cost of Revenue	27.7	27.6	28.4	28.3
Gross Profit	48.4	44.6	43.7	44.4
Selling, General & Administrative	20.8	19.5	19.7	22.4
Operating Income	27.6	25.1	23.7	21.9
Finance Income	4.3	4.7	3.4	1.9
Finance Costs	0.1	0.2	0.4	-0.1
Pretax Income	31.8	30.0	26.8	24.1
Income Tax Expense	7.5	7.3	3.5	5.6
Net Income	24.3	22.7	23.3	18.5
Total Comprehensive Income	21.9	22.0	22.7	17.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3
Total Assets	868.4	870.8	841.7	816.5
Current Assets	620.2	656.6	643.3	606.1
Cash & Cash Equivalents	26.7	37.8	31.8	225.2
Inventories	78.0	63.0	64.1	62.7
Trade Receivables	64.7	63.3	63.7	62.7
Non-current Assets	248.2	214.2	198.4	210.4
Property, Plant & Equipment	140.7	127.5	116.6	108.4
Intangible Assets	6.2	6.2	5.5	5.4
Total Liabilities	52.1	76.3	47.3	44.8
Current Liabilities	50.0	74.2	46.2	42.5
Non-current Liabilities	2.0	2.1	1.1	2.3
Total Equity	816.4	794.5	794.4	771.7
Share Capital	7.3	7.3	7.3	7.3
Retained Earnings	627.5	603.2	602.4	580.2

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3
Cash from Operating Activities	9.8	30.0	23.6	—
Cash from Investing Activities	1.6	-24.2	-216.2	—
Purchase of Property, Plant & Equipment	14.9	12.0	10.1	—
Cash from Financing Activities	-22.3	-0.4	-0.4	—
Dividends Paid	—	—	0.0	—
Net Change in Cash	-10.9	5.4	-193.0	—

Consolidated (CFS), from DART. 3 fiscal years and 4 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

317450 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	287.3	+6.6%	—	—	—
Operating income	92.5	-0.3%	—	—	—
Net income	81.4	+18.6%	—	—	—
EPS	₩5,578	+18.6%	—	—	—
Operating cash flow	81.6	-1.7%	—	—	—
Shareholders' equity	794.4	+49.4%	—	—	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

317450 Profitability

Ratio	FY2025	FY2024	FY2023
Gross margin	60.6%	62.7%	63.5%
Operating margin	32.2%	34.4%	34.5%
Net margin	28.3%	25.5%	30.7%
Return on equity	12.3%	13.7%	15.8%
Return on assets	11.4%	12.4%	14.3%
Operating cash flow / revenue	28.4%	30.8%	31.4%
Capex / revenue	10.5%	3.8%	1.9%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 317450

Symbol	Last Price
476830Rznomics, Inc.	₩28,200 +6.8%
003850Boryung Corporation	₩9,040 +1.6%
950260Ingenia Therapeutics Inc.(reg.s)	₩15,580 -1.5%
085660Chabiotech Co., Ltd.	₩8,090 +2.1%
476060Onconic Therapeutics, Inc.	₩16,440 -3.9%
041960Komipharm International Co., Ltd.	₩9,710 +3.5%
001060JW Pharmaceutical	₩27,500 +1.3%
456160G2GBIO, Inc.	₩37,950 +5.7%
019170Shinpoong Pharmaceutical Co., Ltd.	₩10,010 -0.9%
358570GI Innovation, Inc.	₩8,090 +6.2%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.